Purpose: Recent preclinical and clinical studies show that dyes that excite and fluoresce in the near-infrared range may be used for tracking and detecting disease targets in vivo. A method for quantifying free dye molecules in antibody conjugate preparations is required for agent batch release and for translation into the clinic. Procedures: Herein, we developed and validated a SDS-PAGE method to determine the percentage of free IRDye 800CW in (DTPA) n -trastuzumab-(IRDye 800) m conjugate sample preparations in which high-performance liquid chromatography (HPLC) assessment of free dye was not possible. Results: The SDS-PAGE assay was accurate and valid for free IRDye 800CW amounts between 38 and 4 mol% of total dye. Gel sample preparation reagent affected the specificity of the assay, and lower and upper limits of quantitation and detection were determined. Conclusion: This method may be applicable to other near-infrared dye-conjugated antibodybased imaging agents in which HPLC assessment of purity is not feasible. This validated method for quality assurance will facilitate the translation of dual-labeled antibody conjugates for nuclear and optical imaging.
Introduction W hile nuclear imaging offers exquisite sensitivity that enables molecular imaging of disease targets for diagnosis and assessing response to therapy, near-infrared (NIR) fluorescence has also shown promising sensitivity for clinical application with microdosage [1, 2] . Unlike nuclear medicine techniques, however, there are no established and validated methods for assessing the purity of NIR-conjugated agents, such as fluorophores, that have a reactive N-hydroxysuccinimide ester for lysine binding on antibodies, antibody fragments, or other proteins. As a comparative example, prior to administration, the radiopurity of a radiopharmaceutical is evaluated, usually by thin layer chromatography (TLC), to assess free isotope versus chelated isotope [3] . Since free, unbound radionuclide can distort or inhibit accurate imaging of the desired target, determination of the percent bound radionuclide is an important parameter to check before administering the agent for imaging. Acceptably low ratios can then be identified to minimize the background for nuclear imaging of in vivo targets.
A similar situation exists for NIR fluorescence, as free dye can create a significant background that can limit the performance of the molecular imaging approach. As with a radiolabeled conjugate, before a fluorescent agent can be administered in vivo, its fluorescence purity needs to be evaluated. Unfortunately, in the case of large proteins, such as antibodies or antibody fragments, the use of size-exclusion high-pressure liquid chromatography (HPLC) for assessing purity can be challenging due to overlapping retention times of the fluorophore and chelators. In addition, unlike radioisotopes, the opportunity for quenching can distort quantification of free and bound fluorophore. In our work to validate "first-in-humans" NIR fluorescent agents, we focused on evaluating dual-labeled trastuzumab by developing and validating an analytical approach to assess the purity of the fluorescently labeled compound.
Trastuzumab (Herceptin ®, Genentech, South San Francisco, CA) is a humanized antibody specific for the HER2/ neu receptor overexpressed on some cancer cells, and HER2/ neu has been used as a marker of certain aggressive breast, ovarian, and stomach cancers [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] .
Radioimmunoscintigraphy studies have employed trastuzumab as well as other therapeutic antibodies [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] because of their high affinity for disease targets, but the short half-life of radionuclides and long circulation times may be responsible for their lack of universal adoption. Recently, we have demonstrated the ability to noninvasively detect lymph nodes following microdosage (i.e., ≤100 μg) of indocyanine green, a weak NIR fluorophore without a functional group for conjugation, suggesting the potential of using NIR fluorophores to label antibodies for high-affinity molecular imaging without concern of isotope half-life [29] [30] [31] [32] . In order to provide a comparative assessment of the performance of NIR fluorescence with nuclear imaging, we have created a dual-labeled trastuzumab that uses the conjugated chelator diethylene triamine pentaacetic acid (DTPA) for sequestering 111 In and the NIR fluorophore (IRDye 800) to provide the optical signal [32] . The combination of both nuclear and fluorescent reporters offers unique opportunities for noninvasive nuclear imaging with subsequent fluorescence image-guided resection without concern of fluorophore half-life.
In this study, we developed and validated a method to ascertain quantities of molar percentages of free, or unbound, IRDye 800CW in preparations of (DTPA) n -trastuzumab-(IRDye 800) m . We examined common validation parameters, such as linearity, detection and quantitation limits, selectivity, precision, accuracy, and range in developing and validating this method [33, 34] . This method may be extended to other NIR-labeled imaging markers as a corollary to TLC used in assessment of radiopurity. The technique may provide a means for validating fluorescent imaging agents prior to human administration.
Materials and Methods

Reagents and Equipment
Trastuzumab was provided in kind from Genentech (South San Francisco, CA). p-SCN-Bn-DTPA (2-(p-isothiocyanobenzyl)diethylenetriaminepentaacetic acid) was purchased from Macrocyclics, Inc. (Dallas, TX), and Sephadex G-25/PD-10 columns from GE Healthcare (Chalfont St. Giles, UK). IRDye 800CW was a gift from LI-COR Biosciences (Lincoln, Nebraska). Dulbecco's phosphate buffer solution, 1X, without calcium or magnesium and without phenol red, was purchased from MediaTech, Inc. (Manassas, VA). Tris-HEPES-SDS running buffer (NuSep #BG163) and 12% acrylamide gels (NuSep #NH11-012) were purchased from ISCBioExpress (Kaysville, UT). Methanol and 1 M potassium phosphate buffer, pH 9.0, as well as NaHCO 3 , sodium carbonate (#497-19-8), were purchased from Fisher Scientific (Houston, TX), and SDS sample buffer (#161-0737) from Bio-Rad (Hercules, CA). Zeba™ desalting spin columns were purchased from Pierce (Rockford, IL). Equipment used included a DU800 spectrophotometer (Beckman Coulter, Fullerton, CA), Labnet gel electrophoresis apparatus (#E2010-P, Edison, NJ), and an Odyssey imaging system (LI-COR, Lincoln, NE). Burdick & Jackson™ high-purity water (#365-4) and EMD sodium chloride (#EMD7710) were purchased from Cardinal Health (Houston, TX). Sodium phosphate dibasic heptahydrate (#S373-500) and sodium phosphate monobasic monohydrate (#S369-500) were both purchased from Fisher Scientific (Houston, TX). HPLC-grade phosphoric acid (#A260-500) was also purchased from Fisher Scientific. Sodium azide (#438456-5G) was purchased from Sigma-Aldrich (Atlanta, GA). A Hitachi LaChrom Elite preparative HPLC system with a L-2200 LaChrom Elite autosampler, a L-2455 LaChrom Elite diode array detector, and a Prep 24 solvent delivery system was used. A TSK-Gel® SW Series 6000XL micrometer-size exclusion column (#808541) and a TSKGel® SW GFC 7-µm guard column (#808543) were purchased from Sigma-Aldrich (Atlanta, GA).
Reagent Preparation
Trastuzumab was coupled with DTPA and IRDye 800CW, using the following procedure modified from the protocol described by Sampath et al. [32] . Trastuzumab was dissolved in 50 mM NaHCO 3 (pH 8.0) at a concentration of 20 mg/ml and then mixed with 2X molar excess of the chelator, p-SCN-Bn-DTPA. After agitation of the mixture at room temperature for 30 min, the conjugated complex was loaded onto a Sephadex G-25/PD-10 column to remove unbound DTPA. The purified DTPA-trastuzumab was either stored at -20°C or immediately used for further IRDye 800CW conjugation. (DTPA) n -trastuzumab was diluted to 1 mg/ml in PBS (pH 7.4), and 1 M potassium phosphate buffer (pH 9.0) was added to the antibody to adjust the pH to 8.5. The molar IRDye 800CW-to-trastuzumab ratio ranged from 1 to 10. The conjugation reaction was performed at room temperature for 2 h, protecting the vial from light. Separation of conjugate from free dye was performed by using a Pierce Zeba™ desalting spin column or a PD-10 desalting column.
For the preparation of dual-labeled conjugate, 111 InCl 3 (in 0.05 M HCl, 34.26 GBq/ml, 925.98 mCi/ml) was diluted in 0.1 N sodium acetate (20 ml/37 MBq) and mixed with (DTPA) ntrastuzumab-(IRDye 800) m for 30 min. The conjugate was purified by Sephadex G-25/PD-10 column centrifugation.
Reagent Quantification
Protein concentration (mg/ml) and dye/protein ratios of conjugates were determined using UV/visible spectrophotometry with a Beck-man DU800 spectrophotometer and calculations as recommended by LI-COR (IRDye 800CW high molecular weight protein labeling kit, part # 928-38040).
HPLC Method
Five samples were prepared for size exclusion chromatography (SEC) HPLC analysis. Trastuzumab (100 µg injection), IRDye 800CW (10 µg injection), (DTPA) n -trastuzumab (10 µg injection), and (DTPA) n -trastuzumab-(IRDye 800) m (10 µg injection) were all diluted with HPLC-grade water. DTPA (20 µg injection) was diluted with the mobile phase due to a major inflection peak seen when DTPA was dissolved in HPLC-grade water. The SEC mobile phase consisted of 0.0022 M sodium phosphate buffer (pH 7.4) with 0.14 M NaCl and 0.05% NaN 3 . An isocratic run was performed through the size exclusion column for 20 min at 1 ml/min for each sample.
Gel Sample Preparation
A solution of prepared conjugate ((DTPA)n-trastuzumab-(IRDye 800) m ) was diluted to 0.33 mg/ml. Fourteen microliters of this solution was added to 56 μl of sterile, deionized, distilled water. Ten-microliter aliquots of this dilution were then placed into each of six 1.5-ml Eppendorf polyethylene tubes (the resulting amount loaded onto each gel lane was 2.21 pmol). Unconjugated IRDye 800CW was prepared by diluting a 0.1-mg/ml solution of the dye (in sterile water) at 1:250, 1:375, 1:500, 1:750, 1:1,000, and 1:2,500, and using water (no dye, for background subtraction) only. Ten-microliter samples of these dilutions were added to the tubes containing conjugate. The resulting picomole amounts of free dye loaded per gel lane were 0.858, 0.572, 0.429, 0.286, 0.214, and 0.086. Laemmli/SDS sample buffer at 20 μl was added per tube. The tubes were closed and heated at 95°C for 5 min.
SDS-PAGE and Imaging
Twenty microliters of each of the spiked conjugate solutions were loaded into each of six spaced wells on 12% polyacrylamide gels, and electrophoresis was performed in Tris/HEPES/SDS running buffer for 45 min at 100 V. Gels were removed from the plates and placed directly onto the screen of a LI-COR Odyssey infrared imaging system for measurement of fluorescent intensity at 800 nm at a machine setting of L2.0 intensity. Alternatively, the gels were imaged using illumination light from a laser diode (85 mA and 80 mW for 785-nm light, DL7140-201, Sanyo) that expanded to a circular area approximately 8 cm in diameter. The reemitted fluorescent light was collected with an electron-multiplying charge-coupled device (EMCCD) camera. Filter sets used included a band-pass filter with an 830-nm center wavelength and an optical density of greater than 3 at 785 nm (ANDV8483; Andover Corp., Salem, New Hampshire) for collecting IRDye 800CW fluorescence, and a holographic filter with an optical density of greater than 6 (HSP 785.0; Kaiser Optical Systems, Ann Arbor, MI) for rejecting backscattered and reflected excitation light. Image acquisition was accomplished with V++ software (Total Turnkey Solutions, Sydney, Australia). The integration time for fluorescence images was 800 ms.
Data Analysis
The 16-bit tiff image file from the LI-COR Odyssey system was imported into Image J software (NIH). A region of interest (ROI) of defined pixel size was selected, and integrated intensity measurements were made of each gel band. The total fluorescent counts were acquired using the integrated density setting, since this parameter is not dependent upon a uniform ROI size for all bands analyzed. The gel band associated with (DTPA) n -trastuzumab-(IRDye 800) m corresponded to ∼149 kDa, and free IRDye 800CW was found at ∼1,000 Da. The intensity of each free dye band was divided by the intensity of the corresponding conjugate band to obtain the molar percentage of free dye in the conjugate/dye preparation.
The ratios of free dye determined from these calibrations were then compared to the expected ratios of free dye to conjugate computed from spectrophotometric determination ("Reagent quantification" section above).
In vivo imaging of tumor cells using the dual-labeled antibody-based imaging agent ( 111 In-DTPA) 10 -trastuzumab-(IRDye800) 7 At 24 h after injecting SKBr3-luc xenograft-bearing mice with 80 μg (0.43 nmol, 200 mCi) ( 111 In-DTPA) 10 -trastuzumab-(IRDye800) 7 , near-infrared and planar scintigraphy images were acquired. Near-infrared imaging time was 800 ms, and planar scintigraphy imaging time was 10 min. For near-infrared imaging, mice were illuminated with light from an 80-mW laser diode (DL7140-201, Sanyo) in a circular area of 8-cm diameter. An EMCCD camera collected the reemitted fluorescent light. An 830-nm center wavelength band-pass filter (optical density greater than 3 at 785 nm [ANDV8483, Andover Corporation]) and a holographic filter (optical density greater than 6 [HSP 785.0, Kaiser Optical Systems]) collected IRDye 800CW fluorescence and rejected backscattered and reflected excitation light, respectively. V++ software (Digital Optics) was used for image acquisition, and Image J software (NIH) was used for data analysis. Scintigraphy images were acquired by removing the 3-mm pinhole collimator of a SPECT MicroCAT II scanner (Siemens Medical Solutions), adding a 1.22-mm planar collimator, and integrating for 10 min. Complementary bioluminescence images were collected with 5-min exposure in a light-tight imaging chamber (UVP) with an EMCCD camera (PhotoMAX512B, Princeton Instruments) after i.p. injection of 100 μl of 1 mM D-luciferin (Marker Gene Technologies, Inc.).
Results
Assay Development
Identification of Gel Bands Fig. 1a shows a representative gel, with (DTPA) n -trastuzumab-(IRDye 800) m conjugate and free dye bands marked with arrows. The conjugate molecular weight is ∼149 kDa, and the free dye molecular weight is 1.1 kDa. Addition of beta-mercaptoethanol to the loading buffer, however, produced another band at ∼2 kDa (Fig. 1b) . The extra band at ∼2 kDa may be a product of beta-mercaptoethanol forming an adduct with indole rings of the IRDye 800CW, possibly resulting in substitution at the phenoxy group of the dye, with subsequent linking of dye molecules to form dimers or other multimers (Dan Draney, LI-COR Biosciences, personal communication). All subsequent measurements were conducted without the use of betamercaptoethanol so that true free dye bands were easily identifiable, and selectivity (the ability of an assay to measure the analyte of interest in the presence of other constituents in the sample) was properly addressed. Fig. 2 shows the approximately linear increase in fluorescence intensity per mole of conjugate per dye/protein ratio of conjugates, indicating minimal to nonexistent quenching at higher dye/protein ratios. Fig. 3a illustrates the image of a SDS-PAGE gel of IRDye 800CW in adjacent and spaced lanes on a 12% acrylamide gel. Standard deviations of integrated intensities were reduced when spaced lanes were used, as the diffusion of dye into adjoining lanes was avoided. Fig. 3b shows three images of the same gel obtained immediately, 10 min, and 30 min after electrophoresis. At times greater than 10 min following electrophoresis, gel imaging resulted in leaking of the small IRDye 800CW molecule out of gel lanes. Gel running temperature (4°C versus 21°C) did not appreciably affect the standard deviations, nor did percentage of acrylamide in gels (10%, 12%, 4-20% gradient). Fig. 4 shows HPLC histograms of size exclusion chromatography of trastuzumab, DTPA, IRDye 800CW, (DTPA) n -trastuzumab, and (DTPA) n -trastuzumab-(IRDye 800) m . Retention times were 9.26, 12.39, 12.51, 8.85, and 8.80 min, respectively.
Practical Considerations
HPLC Fractionation Attempts
Assay Validation
After developing and testing the specificity of the SDS-PAGE assay, we conducted a series of validation experiments to characterize the robustness of the assay to determine the linearity, limits of detection and quantification, precision, and accuracy.
Linearity of Calibration Standard Curve One parameter of method validation is linearity, which can be analyzed by producing a regression line for a plot of analyte concentration versus fluorescence (33, 34) . The linearity of this method was evaluated by linearly regressing the fluorescence intensity versus moles of IRDye 800CW in five calibration standards. The average correlation coefficient of 0.9999 from six standard curves provided a "goodness of fit." Fig. 5 shows three standard curves, along with the regression equations. Precision for individual points on the curve, as determined by the coefficient of variation (%CV) values, ranged from 2.3% to 15.8%.
Lower Limit of Detection Detection of the lower limit can be based on the standard deviation of the blank [33, page 11]. The lower limit of detection (LOD), used to define sensitivity, was measured by assaying 6 replicates of zero (H 2 O added instead of dye) four times. The grand mean fluorescence intensity and pooled standard deviation of zero were calculated. The mean of each standard (in linearity assay; Fig. 5 ) was used for the standard curve, and the mean signal of zero plus two standard deviations, read in dose from the standard curve, is the lower limit of detection (LLD)-that is, the smallest dose that is not zero with 95% 4104  2910  1336  2580  634  3790  2942  1352  1728  1172  3792  2136  1780  1086  1266  3792  2136  1780  1086  1266  3750  1996  1134  1072  1628  3750  1996  1134  1072  1628  4554  1740  1204  976  564  4554  1740  1204  976  564  3182  1689  1634  923  466  3182  1689  1634  923  466 Grand Fig. 6. Calculations for lower limit of detection. The lower limit of detection used to define sensitivity was measured by assaying six replicates of zero (H 2 O added instead of dye) four times. The grand mean fluorescence intensity and pooled standard deviation of zero were calculated. The mean of each standard (in linearity assay; Fig. 5 ) was used for the standard curve, and the mean signal of zero plus two standard deviations, read in dose from the standard curve, is the LLD. The lower limit of detection of free IRDye 800CW in this assay was found to be 7.1×10 −3 pmol.
confidence. The lower limit of detection of free IRDye 800CW in this assay was found to be 7.1×10 −3 pmol. The calculations are shown in Fig. 6 . LOD is the same as LLD and the detection limit and is the lowest quantity of a substance distinguishable from the absence of the substance, within a confidence limit, in this case 1%.
Lower Limit of Quantification for Molar Percentage of Free Dye Determination The lower limit of quantitation (LLOQ), according to the FDA's "Guidance for Industry, Bioanalytical Method Validation" [34] , is the lowest concentration of the standard curve that can be measured with acceptable accuracy and precision and should serve as the lowest concentration on the standard curve, if the analyte response at the LLOQ is at least five times the response compared to blank response, and the analyte response is identifiable, discrete, and reproducible. The lower limit of quantification of free IRDye 800CW in this assay for free dye determination is 0.086 pmol.
Upper Limits of Quantification and Detection According to the FDA's "Guidance for Industry, Bioanalytical Method Validation [34] ," the highest standard will define the upper limit of quantification of an analytical method and should be "the highest amount of an analyte in a sample that can be quantitatively determined with precision and accuracy." Fig. 7 shows that the highest standard before encountering pixel saturation and loss of accuracy when measuring fluorescence intensity is 17. 15 pmol. The upper limit of quantification of free IRDye 800CW in this assay is 17.15 pmol. The upper limit of free dye that could be accurately detected in 12% Tris-glycine gels, using a LI-COR Odyssey system at a reading intensity of L2.0, was also determined. At this setting, pixel saturation occurred above 18.5 pmol. Individual pixel intensity measurements of dye concentrations over this limit would underrepresent high-intensity (965,500) pixels, yielding inaccurate gel band intensities.
Precision and Accuracy of Determination of Percentage of Free Dye in Conjugate
We quantified free dye moles of standard amounts of free dye (representing 3-38% of the molar percentage of bound dye in (DTPA) n -trastuzumab-(IRDye 800) m conjugates) run together in gel wells with known amounts of conjugates and determined their relative molar percentages. We used conjugate samples with two different dye/protein ratios to see if this ratio affected the assay. Fig. 8a shows the results of quantitation for a 
Discussion
Many experimental agents can be tested for purity using HPLC analysis. Unfortunately, we found that distinct quantification of free dye using a size-exclusion HPLC method was not possible, because free DTPA and free
IRDye 800CW eluted at almost identical timepoints. We then tested a polyacrylamide gel separation-based assay to quantitate unbound dye in our conjugate preparations. In the process of developing and validating this assay for free dye determination in (DTPA) n -trastuzumab-(IRDye 800) m conjugates samples, we first determined whether several assay features affected the validation parameters. Gel sample preparation reagent, for example, affected the specificity of the assay. When beta-mercaptoethanol was included in the sample running buffer, an extra band appeared near the "true" free dye band. Accuracy (nearness to expected values) and precision (%CV) were affected by gel band spacing, since standard deviations greatly increased a b d c when samples were run in adjoining lanes, allowing overlap of fluorescence. Quenching did not seem to occur in conjugates with dye-to-protein ratios over 2.0, so this method could be applied to such conjugates. The lower limit of detection was calculated here using a zero/standard deviation method, and this agreed with our efforts to identify the lowest identifiable, non-zero amount of free dye (data not shown). The lower and upper limits of quantitation, as well as the upper limit of detection, were set at values according to FDA guidance document recommendations [34] .
After developing a standard operating procedure for this assay, we then validated the assay by testing linearity and comparing actual to expected values of fluorescence intensity. %CVs of fluorescent intensity values for dye amounts within the limits of quantitation were under 20%, and the linearity of fluorescent intensity versus dye amounts was excellent (R 2 =0.9999). In this study, we focused on using IRDye 800CW for two reasons. First, the dye has an emission wavelength in the optimal near-infrared range for imaging mammalian tissue, which is ∼800 nm, where absorbance by hemoglobin, melanin, and water are minimal. Second, we have performed preclinical safety and toxicity studies on IRDye 800CW, in anticipation of extending studies into humans. This assay could be adapted for use with other optical dyes, if a suitable instrument or method is available for fluorescence intensity measurement of gel bands, which could be excised and measured in wells of plates on fluorescence plate readers.
The use of near-infrared optical agents for noninvasive in vivo imaging holds great promise. Fig. 9 shows images obtained using trastuzumab with both optical (IRDye 800) and nuclear ( 111 In) labels in a murine model of breast cancer. Despite background from excitation light leakage (see [31] for discussion), the near-infrared fluorescent images yield high tumor-to-muscle intensity ratios (range 2.2-2.6). Duallabeled imaging agents can help ascertain the accuracy, usefulness, and appropriate applications for optical imaging moieties, as compared to and in addition to nuclear agents. To our knowledge, this is the first purity validation study of an optical imaging agent conjugate. As optical imaging expands into clinical applications, such validations will be necessary to ensure the purity of agents used.
Conclusions
A crucial parameter for in vivo molecular imaging is the minimization of the amount of free, unconjugated dye or tracer in the conjugate preparation to ensure detection of only conjugate-binding cells, and not free dye or free dyebinding cells. In this study, we describe a simple and rapid method for quantifying free/unconjugated dye in (DTPA) ntrastuzumab-(IRDye 800) m conjugate samples and address validation parameters of accuracy, precision, selectivity, range, and limits of detection and quantitation.
We found the assay to be accurate and valid for free IRDye 800CW amounts between 0.086 and 0.86 pmol of free dye that may be present in a 2.2-pmol conjugate sample. Alternate gel lanes must be used to prevent spillover fluorescence from neighboring gel lanes, beta-mercaptoethanol must be omitted from the SDS sample buffer, and gels must be imaged within 10 min of electrophoresis to prevent diffusion of the free dye molecule. The mean lower limit of quantification for this assay for linearity was 0.086 pmol, and the upper limit was 17.15 pmol. The lower limit of detection of dye was 7.1×10 −3 pmol, and the upper limit of detection of dye in this assay was 18.5 pmol. This method may be applicable to other near infrared dye-conjugated imaging agents in which HPLC assessment of purity is not feasible.
